TABLE 2.
Frequencies (%) of driver mutations in the five groups (A‐E) proposed
| A (184) | B (15) | C (79) | D (46) | E (166) | |
|---|---|---|---|---|---|
| EGFR | 72.3 | 0.0 | 74.7 | 0.0 | 11.5 |
| ERBB2 | 4.9 | 0.0 | 1.3 | 0.0 | 1.8 |
| MET | 2.7 | 0.0 | 5.1 | 0.0 | 1.2 |
| ALK | 1.1 | 60.0 | 2.5 | 0.0 | 1.2 |
| ROS1 | 1.1 | 20.0 | 0.0 | 0.0 | 0.0 |
| RET | 0.0 | 6.7 | 0.0 | 0.0 | 0.0 |
| BRAF | 0.5 | 0.0 | 1.3 | 0.0 | 3.6 |
| KRAS | 2.2 | 0.0 | 0.0 | 55.4 | 18.1 |
| NRG1 | 0.0 | 0.0 | 0.0 | 10.9 | 0.0 |
| NONE | 13.6 | 13.3 | 16.5 | 34.8 | 63.3 |
Lung adenocarcinomas surgically resected in Kanagawa prefectural cardiovascular center hospital were examined. Number in each of the groups is shown in parentheses after the alphabets.